Evogene Ltd. (NASDAQ: EVGN) was the target of a significant increase in short interest during the month of December. As of December 15, there was short interest totaling 602,500 shares, an increase of 20.9% from the total of 498,400 shares as of November 30. About 1.6% of the company’s shares are sold short. Based on an average trading volume of 302,100 shares, the short-term interest ratio is currently 2.0 days.
NASDAQ: EVGN shares traded down $ 0.01 in Friday’s midday session, reaching $ 1.61. 735 shares of the stock were traded, for an average volume of 271,288. The company has a 50-day moving average price of $ 2.07 and a 200-day moving average price of $ 2.62. Evogene has a twelve-month low of $ 1.58 and a twelve-month high of $ 10.24. The stock has a market cap of $ 41.46 million, a P / E ratio of -2.14 and a beta of 1.24.
Evogene (NASDAQ: EVGN) last reported its results on Tuesday, November 16. The biotech company reported ($ 0.19) earnings per share for the quarter, missing the consensus estimate of ($ 0.17) of ($ 0.02). Evogene had a negative net margin of 3,013.61% and a negative return on equity of 40.83%. The company posted revenue of $ 0.15 million in the quarter, compared to analysts’ estimates of $ 0.14 million. During the same period of the previous year, the company posted ($ 0.17) EPS. As a group, sell-side analysts expect Evogene to post earnings per share of -0.72 for the current year.
Institutional investors and hedge funds have recently bought and sold shares in the company. Wells Fargo & Company MN increased its stake in Evogene by 164.9% in the 2nd quarter. Wells Fargo & Company MN now owns 7,946 shares of the biotech company valued at $ 27,000 after purchasing an additional 4,946 shares during the period. Crestwood Advisors Group LLC purchased a new stake in Evogene in the 3rd quarter for a value of approximately $ 37,000. XTX Topco Ltd purchased a new stake in Evogene in the 2nd quarter for a value of approximately $ 72,000. Geode Capital Management LLC increased its stake in Evogene by 40.9% in the 2nd quarter. Geode Capital Management LLC now owns 26,731 shares of the biotech company valued at $ 91,000 after purchasing an additional 7,761 shares during the period. Finally, Occudo Quantitative Strategies LP purchased a new stake in Evogene in the second quarter for a value of approximately $ 94,000. Institutional investors hold 28.77% of the company’s shares.
EVGN has been the subject of a number of research reports. Zacks Investment Research downgraded Evogene’s stock from a “hold” rating to a “sell” rating in a research report on Monday, November 22. Royal Bank of Canada lowered its price target on Evogene stock from $ 8.00 to $ 7.00 and established an “outperformance” rating on the stock in a research report released on Wednesday, November 24. . Finally, Roth Capital launched coverage on Evogene shares in a research report on Friday, October 8. They issued a “buy” note and a target price of $ 7.00 on the stock.
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for the improvement of product development processes in the field of life sciences. It operates in the following segments: agriculture, industrial applications and human health. The Agriculture segment develops characteristics of seeds, agrochemicals and agrobiological products to improve plant performance.
See also: What does a bar chart display?
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in Evogene now?
Before you consider Evogene, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of… and Evogene was not on the list.
While Evogene currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here